title: A study of leprosy reactions in a tertiary hospital in Delhi.
abstract: A retrospective study of 531 leprosy patients was undertaken to study the profile of reactions in the post Multi-Drug-Therapy period in a tertiary hospital in Delhi. BT was the most common group. The prevalence of reactions was found to be 8.09% for the Type 1 and 4.70% for the Type 2 reactions for a male:female ratio of 2.2. The Type 1 reaction was most frequently observed in the BB group followed by BL, BT and LL groups respectively. More than half of the patients had reactions at the time of presentation. In only 39.8% of the patients did reaction follow Multi-Drug-Therapy. In 4.5% of the patients with Type 1 reactions (T1R), concomitant infections were noted. The most common presentation of T1R was cutaneous lesions (74.41%) followed by cutaneous lesions and neuritis (53.6%), neuritis alone (12.1%), and only edema of hands and feet (7.31%) respectively. The Type 2 reactions (T2R) presented chiefly as papulo-nodular (92%) lesions followed by pustulonecrotic (8%) lesions. Associated neuritis was found in 40% and periosteitis and iritis in 8% and 4%, respectively. In 8.6% of the patients with T2R, precipitating factors could be observed. The prevalence of deformities in patients with reaction was 25%, and was more common in females. Deformities were observed in 23.25% of the T1R patients and 28% of the T2R patients.
authors.affiliation: Department of Dermatology & Sexually Transmitted Diseases, Lady Hardinge Medical College & S.S.K. and K.S.C. Hospitals, New Delhi, India.
authors.forename: Neelu
authors.initials: N
authors.lastname: Sharma
authors.forename: Ravindra V
authors.initials: RV
authors.lastname: Koranne
authors.forename: Vibhu
authors.initials: V
authors.lastname: Mendiratta
authors.forename: Ravi Chandra
authors.initials: RC
authors.lastname: Sharma
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004338:Drug Combinations; D004487:Edema / Q000503:physiopathology; D004893:Erythema Nodosum / Q000503:physiopathology; D005260:Female; D005533:Foot Dermatoses / Q000503:physiopathology; D006229:Hand Dermatoses / Q000503:physiopathology; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000503:physiopathology; D007105:Immune Complex Diseases / Q000503:physiopathology; D007500:Iritis / Q000503:physiopathology; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy / Q000503:physiopathology*; D015439:Leprosy, Borderline / Q000188:drug therapy / Q000503:physiopathology; D015440:Leprosy, Lepromatous / Q000188:drug therapy / Q000503:physiopathology; D015441:Leprosy, Tuberculoid / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009443:Neuritis / Q000503:physiopathology; D010522:Periostitis / Q000503:physiopathology; D012189:Retrospective Studies; D012737:Sex Factors
chemical_list: D004338:Drug Combinations; D007917:Leprostatic Agents